Will the drug resistance of ivonib/Tosuvox affect the therapeutic effect?

Ivosidenib/Tosovo(Ivosidenib) is an IDH1-targeting drug, used in relapsed or refractory acute myeloid leukemia(AM L) , cholangiocarcinoma (CCA), myelodysplastic syndrome (MDS) has demonstrated significant efficacy. However, like all targeted therapies, resistance issues may affect long-term treatment efficacy. Resistance can be divided into two types: innate resistance and acquired resistance. Innate resistance refers to a patient's poor response to the drug when initially taking the drug, while acquired resistance refers to cancer cells evading the effects of the drug through mutations, changes in signaling pathways, or metabolic regulation during long-term drug use.

Acquired resistance is a common challenge in the clinical application of ivonib. As treatment continues, some cancer cells may produce secondary mutations in the IDH1 gene or activate alternative signaling pathways, thereby weakening the inhibitory effect of the drug and leading to deterioration of the blood picture or recurrence of abnormal bone marrow morphology. This means that although ivonib can achieve improvement in blood levels and stable disease in the early stage, the emergence of drug resistance may affect the sustainability of the efficacy.

The strategy to deal with drug resistance includes closely monitoring the patient's blood count, bone marrow morphology, andIDH1 mutation status, and if necessary, drug combination therapy or replacement of other targeted drugs. In addition, some studies have shown that early identification of signs of drug resistance and adjustment of treatment options can delay disease progression and improve overall patient benefit. Patients should maintain regular medication during treatment and report abnormal symptoms in a timely manner so that doctors can adjust strategies in a timely manner.

To sum up, drug resistance may indeed affect the therapeutic effect of ivonib, but through individualized management, regular monitoring and scientific adjustment of medication, the drug efficacy can still be maintained to a large extent. Understanding the mechanism of drug resistance can help doctors develop more optimized long-term treatment plans for patients, while providing more stable and sustainable disease control for AML patients.

Reference: https://www.tibsovo.com/